Janet L Anderl Selected Research

Rituximab (Mabthera)

1/2013

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Janet L Anderl Research Topics

Disease

4	Neoplasms (Cancer) 11/2017 - 05/2014
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2023 - 01/2021
2	Rheumatoid Arthritis 01/2023 - 01/2021
2	Autoimmune Diseases (Autoimmune Disease) 04/2017 - 01/2013
2	Multiple Myeloma 12/2014 - 05/2011
2	Hematologic Neoplasms (Hematological Malignancy) 07/2014 - 05/2014
2	Leukemia 07/2014 - 05/2014
1	Lupus Nephritis 01/2023
1	Proteinuria 01/2023
1	Rheumatic Diseases (Rheumatism) 12/2018
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2014
1	Lung Neoplasms (Lung Cancer) 12/2014
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2014
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 07/2014
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2013
1	Peripheral Nervous System Diseases (PNS Diseases) 05/2011

Drug/Important Bio-Agent (IBA)

5	Bortezomib (Velcade)FDA Link 04/2017 - 05/2011
3	KZR-616IBA 01/2023 - 12/2018
3	Proteasome InhibitorsIBA 12/2014 - 01/2013
3	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2014 - 05/2011
2	CytokinesIBA 01/2023 - 11/2017
2	carfilzomibIBA 04/2017 - 12/2014
1	Histocompatibility Antigens Class IIBA 11/2017
1	Cisplatin (Platino)FDA LinkGeneric 12/2014
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 12/2014
1	Caspase 3 (Caspase-3)IBA 12/2014
1	marizomibIBA 07/2014
1	antineoplaston A10 (A 10)IBA 05/2014
1	Rituximab (Mabthera)FDA Link 01/2013
1	DipeptidesIBA 05/2011